Cytoplasmic PML promotes TGF-β-associated epithelial–mesenchymal transition and invasion in prostate cancer by Buczek, ME et al.
OPEN
ORIGINAL ARTICLE
Cytoplasmic PML promotes TGF-β-associated epithelial–
mesenchymal transition and invasion in prostate cancer
ME Buczek1, AK Miles1, W Green2, C Johnson1, DJ Boocock1, AG Pockley1, RC Rees1, G Hulman3, G van Schalkwyk4, R Parkinson2,
J Hulman3, DG Powe1,3,5 and T Regad1,5
Epithelial–mesenchymal transition (EMT) is a key event that is involved in the invasion and dissemination of cancer cells. Although
typically considered as having tumour-suppressive properties, transforming growth factor (TGF)-β signalling is altered during
cancer and has been associated with the invasion of cancer cells and metastasis. In this study, we report a previously unknown role
for the cytoplasmic promyelocytic leukaemia (cPML) tumour suppressor in TGF-β signalling-induced regulation of prostate cancer-
associated EMT and invasion. We demonstrate that cPML promotes a mesenchymal phenotype and increases the invasiveness of
prostate cancer cells. This event is associated with activation of TGF-β canonical signalling pathway through the induction of Sma
and Mad related family 2 and 3 (SMAD2 and SMAD3) phosphorylation. Furthermore, the cytoplasmic localization of promyelocytic
leukaemia (PML) is mediated by its nuclear export in a chromosomal maintenance 1 (CRM1)-dependent manner. This was clinically
tested in prostate cancer tissue and shown that cytoplasmic PML and CRM1 co-expression correlates with reduced disease-speciﬁc
survival. In summary, we provide evidence of dysfunctional TGF-β signalling occurring at an early stage in prostate cancer. We show
that this disease pathway is mediated by cPML and CRM1 and results in a more aggressive cancer cell phenotype. We propose that
the targeting of this pathway could be therapeutically exploited for clinical beneﬁt.
Oncogene advance online publication, 9 November 2015; doi:10.1038/onc.2015.409
INTRODUCTION
The gene encoding the promyelocytic leukaemia (PML) tumour
suppressor is a member of the Ring-B box-Coiled Coil family,
originally identiﬁed at the breakpoint of the t(15;17) translocation
found in acute promyelocytic leukaemia (APL).1–3 PML is involved
in the regulation of many cellular pathways such as apoptosis,
senescence, response to DNA damage and resistance to viral
infection.4–7 Although the function of PML has been extensively
investigated because of its essential role in the formation of PML-
nuclear bodies (PML-NBs), the subcellular localization of PML is not
restricted to the PML-NBs and is observed in other cellular
compartments including the nucleoplasm, the nucleolus, the
nuclear envelope and the cytoplasm.5,8 The roles of PML in these
cellular compartments remain unclear, and may involve mechan-
isms that are independent of PML-NBs. There are seven main
isoforms of PML (I–VIIb), which appear to have cellular functions
that are related to their expression pattern in physiological and
pathological cellular contexts. Most of the isoforms contain the
nuclear localization signal (NLS), which enables them to localize in
the nucleus (PMLI to PMLVI), whereas PMLVIIb lacks the NLS and is
found in the cytoplasm.9 The PMLI isoform also possesses a
nuclear export signal (NES), which allows its nuclear export in a
CRM1-dependent manner.10
Recent studies suggest the involvement of cytoplasmic PML in
tumorigenesis, glycolysis, anti-viral responses, laminopathies and
cell cycle regulation.8 In a physiological context, cytoplasmic PML
has been shown to activate transforming growth factor (TGF)-β
signalling, a cellular pathway involved in tumour suppression,
apoptosis and senescence.11–13 Furthermore, defects in TGF-β
signalling in Pml− /− mouse embryonic ﬁbroblasts have also been
reported.14 TGF-β binding to its receptors results in the
phosphorylation of the SMAD proteins, a cellular event that is
facilitated by the TGF-β-receptor adapter SARA (SMAD Anchor for
Receptor Activation). This process results in the translocation of
SMADs to the nucleus and the activation of target genes.15 In this
context, cytoplasmic PML appears to favour the interaction of
SARA and the SMAD protein members, SMAD2 and SMAD3.14
Although TGF-β signalling is a potent inhibitor of cell proliferation,
this function seems to be altered in tumour cells, in that it acts as
an oncogene.16–21 In particular, defects in normal TGF-β signalling
have been shown to trigger tumorigenic events including cancer-
associated epithelial–mesenchymal transition (EMT), an important
process that is involved in the progression of advanced
tumours.22,23 Based on this background, we hypothesized that
cytoplasmic PML promotes cancer-associated EMT and local
tumour invasion via the induction of TGF-β signalling. Further-
more, we reveal a new role for cytoplasmic PML (cPML) in the
progression of prostate cancer. To better understand the role of
cPML in tumour progression, we investigated its inﬂuence on EMT
and cell invasion using prostate cancer cell lines and mutant
constructs. Furthermore, we showed the translational importance
of this proposal in a clinical setting by showing that cPML
expression correlates with the expression of the nuclear export
factor CRM1 (Exportin-1), and is associated with a worse prognosis.
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These studies demonstrate that cPML induces cell invasion by
promoting the transdifferentiation of epithelial cells into
mesenchymal cells involving TGF-β signalling, via SMAD2
and SMAD3 phosphorylation. Collectively, these results support
the concept that cPML promotes TGFβ-induced EMT promoting
a more aggressive cancer cell phenotype resulting in increased
cell invasion and reduced survival for patients with prostate
cancer.
RESULTS
PML cytoplasmic localization is mediated by CRM1-dependent
nuclear export
PML expression is altered in cancers of various histological
origins.24 To investigate the expression status of PML, we
performed immunostaining on prostate adenocarcinoma tissues
using an antibody against PML. In normal prostate tissue, PML was
expressed in the nucleus of cells within the prostate gland. The
expression was typical of that of PML-NBs (Figure 1a). In contrast,
PML expression was decreased (Figure 1b, upper panel) or
exhibited nucleo-cytoplasmic and/or cytoplasmic expression
patterns (Figure 1b, lower panel) in prostate adenocarcinoma
cells. Similar results were obtained by immunoﬂuorescence (IF), in
that PML is expressed in the nucleus of the normal prostate cell
line PNT2, and in the nucleo-cytoplasm and/or cytoplasm of the
prostate cancer cell lines DU145, PC3 and LNCaP (Figures 1c and d).
Although the decrease of PML expression in cancer tissues has
been previously reported, PML localization in the cytoplasm
and its role in that cellular compartment are not understood.
To investigate this, we performed immunoprecipitation (IP)
experiments using a PML antibody and whole-cell extracts from
DU145 human prostate cancer cells. The efﬁciency of the IP
was determined by investigating the presence of PML in
PML-immunoprecipitates and using immunoblotting (IB) with
PML antibody. PML immunoprecipitates were also used to
identify PML-interacting partners using MALDI-TOF mass spectro-
metry. PML and several molecules were identiﬁed as PML-interacting
partners (Figure 1e). Interestingly, one of the interacting proteins
identiﬁed was CRM1 (Exportin-1), a molecule which is involved in
nuclear export. Therefore, the cytoplasmic localization of PML
within prostate cancer cells might be a consequence of its nuclear
export in a CRM1-dependent manner. To conﬁrm the interaction
of PML with CRM1, IP of DU145 extracts with a PML antibody was
performed (Figure 1f). In addition to PML, CRM1 was also pulled
down as demonstrated by IB of the immunoprecipitates with PML
and CRM1 antibodies. Finally, the nuclear export of endogenous
PML in DU145 and PC3 cells was markedly decreased after
treatment with Leptomycin B, an inhibitor of nuclear export
mediated by CRM1 (Figure 1g). Taken together, these results
demonstrate that the cytoplasmic localization of PML in prostate
cancer cells involves, at least in part, a CRM1-dependent nuclear
export.
Clinical signiﬁcance of cytoplasmic PML and CRM1 expression:
association with poor prognosis
Although previous studies have shown a correlation between the
loss of PML expression and prostate cancer progression,24,25 the
role of cytoplasmic PML in this process is still unclear. To examine
this, the association of CRM1 and PML with cancer-speciﬁc
mortality and metastasis in a cohort of patients with prostate
cancer was investigated by immunohistochemical staining of
prostate cancer tissue microarray (TMA). Both proteins were
variously located within the nuclei of benign prostate tissue
(Figures 2a and c) and in the nuclei and cytoplasm of prostate
cancer tissue and were more abundant in the cytoplasm of
tumours compared with normal prostate tissue (Figures 2b, d
and Supplementary Table 2). Neither nuclear or cytoplasmic
expression of PML, nor the expression of cytoplasmic CRM1
protein alone was found to be predictive of reduced disease-
speciﬁc survival or metastasis (Supplementary Table 2). To test the
hypothesis that PML is transported by CRM1, the capacity of PML/
CRM1 expression to predict clinical outcome was assessed. Eighty
percent (40/50) of patients exhibited either complete loss of PML
and CRM1 in tumours or simultaneous expression of cytoplasmic
PML and CRM1. This patient group showed reduced cancer-
speciﬁc survival (χ2 = 6.47, P= 0.011) over a 10-year term
(Figure 2e), but not signiﬁcantly increased metastasis over the
same term (χ2 = 3.108, P= 0.078). A Cox proportional hazards
regression model demonstrated that simultaneous expression
of cytoplasmic PML/CRM1 predicted reduced disease-speciﬁc
survival that was independent of prostate-speciﬁc antigen levels
(44 ng/ml) and the Gleason score (47; hazard ratio = 0.264,
P= 0.009, 95% conﬁdence interval = 0.097–0.720).
The cytoplasmic fraction of PML promotes cell invasion and EMT
Although, PML and CRM1 do not appear to signiﬁcantly correlate
with metastasis in prostate cancer, the cytoplasmic localization of
PML as a result of CRM1 nuclear export may be an early event,
which has a role in tumour invasion of adjacent tissues. To
investigate the role of cytoplasmic PML on cell migration and
invasion, we generated three PMLI haemagglutinin (HA)-tagged
mutant constructs: PMLI wild-type HA, PMLI ΔNLS-HA (without the
NLS) and PMLI ΔNES-HA (without the NES). The constructs were
stably expressed in DU145 and PC3 prostate cancer cell lines using
a lentiviral expression system (Figure 3a). Their protein expression
pattern was investigated by IB and IF (Figures 3a and b), and the
effect of expression on cell migration and invasion determined
using wound healing (Scratch assay), well cell migration and well
cell invasion assays. Interestingly, DU145 and PC3 cells expressing
PMLI ΔNLS exhibited an increased migration and invasive
capacities in comparison to cells expressing the empty vector,
PMLWT-HA and PML ΔNES constructs (Figures 3c–h and
Supplementary Figures 2a and b). Furthermore, knockdown of
endogenous PML in DU145 and PC3 resulted in a decreased cell
migration. Treatment of these cells with Leptomycin B also
affected cell migration (Supplementary Figure 2c). Finally, CRM1
knockdown in DU145-expressing PMLI ΔNLS did not signiﬁcantly
affect cell migration (Supplementary Figure 3d). The increased cell
migration and invasion observed in the presence of PMLI ΔNLS
was not caused by increased proliferation (Supplementary Figure
3e). These results suggest that the cytoplasmic fraction of PML
promotes the migration and invasive capacities of prostate
cancer cells.
The expression of PML constructs also inﬂuenced the cellular
morphology of DU145 and PC3 prostate cancer cells. Notably, cells
expressing the PML ΔNLS-HA construct exhibited a mesenchymal
phenotype, which was characterized by the presence of individual
elongated cells. In contrast, DU145 and PC3 cells expressing PML
ΔNES-HA exhibited a more epithelial phenotype. The cells
expressing the wild-type construct presented an intermediate
phenotype, which was probably a result of its dual nuclear and
cytoplasmic expression (Figures 4a and b). To conﬁrm these
observations, we performed IF on these cells using antibodies that
recognize key markers of epithelial cells (E-Cadherin) and
mesenchymal cells (Vimentin and and N-Cadherin). Lower
E-cadherin expression and increased expression of Vimentin and
N-Cadherin were observed in cells expressing PML ΔNLS. On the
contrary, cells expressing PML ΔNES-HA, expressed higher levels of
E-Cadherin, but a lower expression of Vimentin and N-cadherin.
Some of the cells that expressed PML WT-HA exhibited a higher
expression of E-Cadherin, whereas others expressed higher
levels of Vimentin and N-Cadherin. To conﬁrm these observa-
tions, we performed IB of lysates from cells expressing the
empty vector, PML WT-HA, PML ΔNLS-HA and PML ΔNES using
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Figure 1. PML expression in normal and cancer prostate cells. (a and b) Immunohistochemistry/ﬂuorescence micrographs showing PML
expression (green) in normal prostate tissue and prostate adenocarcinoma. The nucleus is stained in blue (4,6-diamidino-2-phenylindole
(DAPI)). Scale bar= 100 μm. (c and d) Immunoﬂuorescence micrograph showing PML expression (red) in normal prostate cell line (PNT2)
and in prostate cancer cell lines (DU145, PC3 and LNCaP). Scale bar= 20 μm. (e) Schematic representation of the methodology used to
identify PML-interacting partners from DU145 cell extracts using immunoprecipitation (IP) with PML antibody and MALDI-TOF mass
spectrometry. (f) Immunoprecipition of DU145 cell extract with PML antibody and immunoblotting (IB) with PML and CRM1 antibodies.
(g) Immunoﬂuorescence micrograph showing PML expression in DU145 and PC3 treated with or without Leptomycin B (15 ng/ml). Scale
bar= 20 μm.
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antibodies recognizing key markers of epithelial and mesench-
ymal phenotypes (Figures 4c and d). PMLΔNLS cells expressed
lower levels of epithelial markers and higher levels of
mesenchymal markers (Figures 4c and d). PMLΔNES expressed
higher levels of epithelial markers and lower levels of
mesenchymal markers. These results demonstrate that
cytoplasmic PML promotes EMT, whereas nuclear PML promotes
an epithelial phenotype.
Cytoplasmic PML-induced EMT and cell invasion are mediated by
TGF-β signalling
To investigate the potential involvement of TGF-β signalling
pathway in PML-mediated EMT and cell migration and invasion,
we performed IB of lysates from DU145 and PC3 cells expressing
the empty vector, PMLWT-HA, PMLΔNLS-HA and PMLΔNES using
an antibody against the phosphorylated forms of SMAD2 and 3.
Interestingly, higher levels of phospho-SMAD2/3 were observed in
Figure 2. Immunohistochemical localization of PML and CRM1 in prostate cancer patients' TMA. (a) Lack of cytoplasmic PML and (c) CRM1 in
benign tissue. (b) Nuclear and cytoplasmic localization of PML and (d) CRM1 in cancer. (e) Kaplan–Meier plot. Scale bars as indicated.
Figure 3. The migration of DU145 and PC3 cells is promoted by cytoplasmic PML. (a) Schematic representation of PMLI mutant constructs
(PMLI WT-HA, PMLI ΔNLS-HA and PML ΔNES-HA) and their protein expression proﬁles as shown by immunoblotting from DU145 and PC3
whole-cell extracts and using an anti-HA antibody. (b) Immunoﬂuorescence images demonstrating stable expression of PMLI mutants in
DU145 and PC3 cells using an anti-HA antibody. Scale bar= 10 μm. (c, d) Wound healing assay (Scratch assay) using DU145 and PC3 cells
expressing PMLI mutant constructs and the corresponding data quantifying gap closure at time points 0 and 24 h following scratching.
Analysis of variance (ANOVA): ****Po0.0001 and ***P= 0.0001. Scale bar= 200 μm. (e, f) Well cell migration assay using DU145 (left panel) and
PC3 cells expressing PMLI mutant constructs and the data relating to the number of migrated cells after 24 h of culture. ANOVA: **P= 0.0018
and ANOVA: ***P= 0.0002. (g, h) Cell invasion assay using DU145 (left panel) and PC3 cells (right panel) expressing PMLI mutant constructs
and the data relating to the number of migrated cells after 24 h of culture. ANOVA: *P= 0.0108 and ANOVA: *P= 0.0304.
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PML ΔNLS-expressing cells, when compared with cells expressing
the other constructs (Figure 5a). To conﬁrm this result, we
performed IB using the phospho-SMAD2/3 antibody on cell lysates
from DU145 and PC3 cells expressing PML ΔNLS that had been
treated with a speciﬁc TGFβRI inhibitor (untreated cells as
controls). Treatment with the inhibitor signiﬁcantly reduced the
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level of phospho-SMAD2/3 expression, but did not affect cPML
expression (Figures 5b and c). E-Cadherin expression levels were
increased following treatment with the inhibitor (Figures 5b and c),
whereas the expression of N-Cadherin was decreased (Figure 5c).
As the inhibition of TGF-β signalling in this experimental setting
may also affect cell migration, we tested the inﬂuence of the
TGFβRI inhibitor on DU145 and PC3 cells expressing PML ΔNLS
using a wound healing assay. Remarkably, the inhibitor signiﬁ-
cantly reduced the migration-inducing capacity of PML ΔNLS
(Figures 5d and e). This result was conﬁrmed by knocking
down TGF-β receptor I in DU145 cells expressing PML ΔNLS
(Supplementary Figure 3a). Finally, in invasive prostate adenocar-
cinoma tissue, the cytoplasmic expression of PML and CRM1
correlated with the nuclear expression of phospho-SMAD2/3, an
increased expression of N-Cadherin and a decreased expression of
E-Cadherin (Figures 6a and b). Taken together, these results
demonstrate a role of cytoplasmic PML in TGFβ-mediated EMT
and invasion (Figure 7).
DISCUSSION
EMT is a key cellular event that is involved in embryonic
development, wound healing and cancer progression.22,26 The
baso-apical polarity of epithelial cells is maintained through lateral
cell–cell junctions that include desmosomes, adherens junctions,
tight junctions and gap junctions. During EMT, epithelial cells,
which begin their transdifferentiation via the loss of lateral
junctions, start to express molecules associated with the
mesenchymal phenotype and this results in the generation of
mesenchymal cells. These later have an essential role in the spread
of disease to adjacent tissues and other organs via a process called
metastasis. Upon reaching the target organ, these cells begin a
reverse cellular process (mesenchymal–epithelial transition),
which results in the generation of cancer epithelial cells, which
integrate into the structure of target tissue and therefore ‘ignite’
its oncogenic transformation. EMT can be naturally induced by
several cellular pathways such as growth factors, TGF-β, WNT, HH
and Notch signalling. In cancer, these pathways can be altered
and result in cancer-associated EMT. Notably, TGF-β signalling is a
well-known tumour-suppressive pathway, and cancerous cells
circumvent this function by inactivating the anti-proliferative arm
of the pathway or by altering the function of downstream
components of the pathway.27
EMT is induced as a consequence of TGF-β signalling
dysfunction, to result in an increase in the invasion and
dissemination of cancer cells. In this regard, cytoplasmic PML
appears to activate the phosphorylation of SMAD2 and SMAD3,
two main components of the canonical SMAD pathway in
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response to TGF-β. In this study, we observe a similar mechanism,
in that cPML induces TGF-β signalling through cPML induction of
SMAD2 and SMAD3 phosphorylation. However, and in comparison
with Lin et al. study which used a physiological model (mouse
embryonic ﬁbroblasts), our work investigated the role of cPML in
the regulation TGF-β signalling within a pathological setting,
namely prostate cancer. In this context, we showed that cPML
promotes TGF-β-induced prostate cancer-associated EMT and
invasion, a mechanism that was previously unknown (Figure 7).
This difference is not surprising given that the consequences of
TGF-β signalling are dependent on whether the cellular context
is physiological or pathological. Moreover, cPML is mainly found
in the cytoplasm of tumour tissue for patients with prostate
cancer that exhibited a poor clinical prognosis. In addition,
several reports have reported on the oncogenic potential of
cPML mutants.8 Two different PML mutations (1272delAG and
IVS3–1G-A) have been identiﬁed in aggressive APL patients.
The mutations generated a stop codon before the NLS
domain leading to the generation of cPML mutants.24 Other
studies have shown that cPML is upregulated in hepatocellular
carcinoma.28,29 In the present study, we showed increased cPML
and cytoplasmic expression of Exportin-1 (CRM1) in tumour
tissue of patients with prostate cancer correlates with a poor
clinical prognosis, suggesting a functional link between the two
molecules. Indeed, the PMLI isoform is the only known isoform
that contains a NES, and thereby could be exported to the
Normal Prostate Tissue Invasive Prostate Adenocarcinoma Tissue
PML/DAPI PML/DAPI
CRM1/DAPI CRM1/DAPI
pSMAD 2/3/DAPI pSMAD 2/3/DAPI
E-Cadherin/DAPI E-Cadherin/DAPI
N-Cadherin/DAPIN-Cadherin/DAPI
Figure 6. Expression of PML, CRM1, p-SMAD2/3, E-Cadherin and N-Cadherin in normal prostate and invasive adenocarcinoma tissues.
(a, b) Immunohistochemistry/immunoﬂuorescence using antibodies against PML, CRM1, p-SMAD2/3, E-Cadherin and N-Cadherin in normal
prostate tissue (a) and invasive prostate adenocarcinoma tissue (b). Arrows indicates nuclear p-SMAD2/3. Scale bar= 100 μM and 50 μM. DAPI,
4,6-diamidino-2-phenylindole.
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cytoplasm. This possibility has been demonstrated, in that we
have shown that the mutant PMLI which lacked the NES
promoted a more epithelial phenotype, which is associated with
an increased expression of epithelial markers. This suggests that
nuclear PML may prevent cancer-associated EMT and may have
a role in promoting mesenchymal–epithelial transition. Taken
together, these observations highlight the involvement of cPML
in prostate cancer progression and provide further insights on
the role of deregulated TGF-β signalling in pathogenesis of
cancer invasion.
MATERIALS AND METHODS
Antibodies
For this study, we used antibodies to PML (1:250 for IB, 1:100 for IP, sc-966,
Santa Cruz Biotechnology, Delaware Ave., Santa Cruz, CA, USA), PML (1:500
for immunohistochemistry (IHC), sc5621, Santa Cruz Biotechnology,
Delaware Ave.), HA (1:1000 for IB, 1:200 for IF, A190-108 A, Bethyl Laboratories
Inc., Montgomery, TX, USA), β-actin (1:5000 for IB, A5441, Sigma-Aldrich,
St Louis, MO, USA), Exportin-1 (CRM1; 1:5000 for IB, 1:2000 for IHC,
A300-469A, Bethyl Laboratories Inc.), E-Cadherin (1:500 for IF, 610181,
BD Transduction Laboratories, San Jose, CA, USA), EMT antibody Sampler Kit
(9782, Cell Signaling Technology, Danvers, MA, USA), which contains rabbit
antibodies each used at 1:300 (IB), N-Cadherin and Vimentin antibodies were
used at 1:500 for IF, Phospho-Smad2/Smad3 (1:300 for IB, 8828, Cell
Signaling Technology), Phospho-Smad2/3 (1:100 for IHC, sc-11769, Santa
Cruz Biotechnology), Anti-rabbit IgG, HRP-linked Antibody (1:1000 for IB,
7074, Cell Signaling Technology), Anti-TGFβ Receptor I (1:1000 for IB, 3712,
Cell Signaling Technology), Anti-SMAD2 (1:1000 for IB, 3122, Cell Signaling
Technology), Anti-SMAD3 (1:1000 for IB, 9513, Cell Signaling Technology),
Anti-phospho-SMAD2 (1:500, SAB4504207, Sigma-Aldrich), Anti-phospho-
SMAD3 (1:500, SAB4300253, Sigma-Aldrich), Anti-mouse IgG, HRP-linked
antibody (1:1000 IB, 7076, Cell Signaling Technology).
Cell lines, growth conditions, cell fractionation and cell
proliferation assay
DU145 and PC3 prostate cancer cell lines were purchased from American
Type Culture Collection (Manassas, VA, USA) and cultured in Eagle's
Minimum Essential Medium (BE12-6621, Lonza, Basel, Switzerland) and
F-12k Nut Mix (1x; 21127-022, Gibco Life Technologies, Waltham, MA, USA)
respectively. The media were supplemented with 10% (v/v) fetal calf serum
and 1% (w/v) L-glutamine (Lonza). Cells were incubated at 37 °C in 5% (v/v)
CO2 and 100% (v/v) humidity. For the relevant experiments, cells were
treated for 48 h with 3 μM of TGFβR1 inhibitor SB431542 (1614, Tocris
Bioscience, Moorend Farm Avenue, Bristol, UK) and for 20 h with 15 ng/ml
of Leptomycin B. TGF-β1 was purchased from PeproTech (London, UK)
(100-22) and used at 10 ng/ml. Cell proliferation was quantiﬁed using
CyQUANT NF Cell Proliferation Assay Kit (C35006, Invitrogen, Waltham, MA,
USA).
Retroviral expression of PML constructs
The PMLI gene fragment was obtained by PCR ampliﬁcation from
pcDNA3.1-PMLI (a kind gift from Dr Mounira Chelbi-Alix, University PARIS V)
using forward primer SpeI/PML F′: 5′-CATCTAACTAGTATGGAGAGCCTGC
P
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Figure 7. Schematic representation of the role played by cytoplasmic PML in promoting TGF-β signalling in tumour microenvironment. PML is
exported from the nucleus to the cytoplasm in a CRM1-dependent manner. Cytoplasmic PML interacts and promotes the association of SARA
with SMAD2 and SMAD3, which activates their phosphorylation. Phosphorylated SMAD2 and SMAD3 interact with SMAD4 and translocate to
the nucleus where they regulate gene expression of factors involved in promoting EMT and invasion. During EMT, epithelial cells characterized
by the expression of epithelial markers and a baso-apical polarity start to lose their cell–cell contacts and to express mesenchymal markers
characteristic of mesenchymal cells. The later have a high migratory and invasive properties and have a key role in cancer progression.
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ACCCGCCC-3′ and reverse primer PML R′/BamHI 5′-CATCTAGGATCCTCAGC
TCTGCTCGGAGGCC-3′ (Euroﬁns MWG Operon). The fragment obtained
was cloned into the pLKOpuro vector using the SpeI and BamHI restriction
sites (SHC001, Sigma, St Louis, MO, USA). An HA-tag was introduced in the
C-terminal end of PMLI by PCR using QuikChange Site-Directed Mutagen-
esis Kit (200518, Stratagene, Cedar Creek, TX, USA) and the following
primers: HA-tag-sense 5′-CCTCCCAGCAGAGCTACCCTATCGATGTTCCAGATT
ACGCTTGAGGATCCACCGG-3′ and HA-tag-antisense 5′-CCGGTGGATCCTCA
AGCGTAATCTGGAACATCGTATGGGTAGCTCTGCTGGGAGG-3′. The deletions
of PMLI NLS and PMLI NES were also performed by PCR using QuikChange
Site-Directed Mutagenesis Kit using ΔNLS-sense 5′-GCCCCAGGAAGGTCGG
GAAGGAGGCAAG-3′; ΔNLS-antisense 5′-CTTGCCTCCTTCCCGACCTTCCTGG
GGC-3′ or ΔNES-sense 5′-ACATTAACAGGCTGTGGGAAGTGCCCGGGGC-3′;
ΔNES-antisense 5′-GCCCCGGGCACTTCCCACAGCCTGTTAATGT-3′. The lenti-
viral particles used to infect DU145 and PC3 with pLKO-PML constructs were
produced according to the manufacturer’s recommendations. The lentiviral
packaging mix was also purchased from Sigma (SHP001).
Stable and transient transfection of cell lines
The transient knockdown of CRM1 and TGFβRI was carried out using an
CRM1- or TGFβRI-speciﬁc small interfering RNA molecule (CRM1 small
interfering RNA (h), sc-35116, Santa Cruz Biotechnology, Inc; TGFβRI small
interfering RNA (h), sc-40222, Santa Cruz Biotechnology, Inc) and Interferin
transfection reagent (Polyplus, Woodley, Reading, UK) following the
manufacturer’s recommendations. PML lentiviral plasmids short hairpin
RNA control and PML short hairpin RNA 1 and 2 were purchased from
Sigma (TRCN0000003866, TRCN0000003869 and SHC001).
Immunoblotting and immunoprecipitation
The experimental procedures were performed as described previously.30
For IB, the cells lysed in 1× solution containing 50mM Tris-HCl (pH 6.8),
100mM dithiothreitol, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue and
10% (v/v) glycerol, and loaded onto Tris/glycine SDS–polyacrylamide gels
for electrophoresis. The proteins were transferred onto Amersham
Hybond-P PVDF membranes (GE Healthcare, Chalfont St Giles, Buck-
inghamshire, UK). Membranes were blocked with 10% (w/v) Marvel milk
powder/tris-buffered saline solution with 0.1% (v/v) Tween-20. Following
washes in tris-buffered saline solution with 0.1% (v/v) Tween-20,
membranes were incubated with primary antibodies (in blocking solution)
overnight at 4 °C followed by washing and incubation with secondary
antibodies for 1 h at room temperature before visualization using Rapid
Step ECL reagent (Calbiochem, San Diego, CA, USA) and a CCD camera
(Fujiﬁlm, Martins Way, Bedford, UK). For IP, the cells were lysed in IP buffer
(0.05 M Tris, pH 7.4, 0.15 M NaCl, 0.5% (v/v) Triton X-100 and 0.001 M EDTA).
The extracts were pre-cleared for 1 h at 4 °C using Protein G Plus–Agarose
beads (IP08, Calbiochem) and corresponding IgG. The PML antibody was
incubated with agarose beads in IP buffer for 2 h before adding the pre-
cleared extracts for overnight IP. The beads were washed four times in IP
buffer and suspended in lysis buffer, after which samples were analysed by
mass spectrometry and IB.
Immunohistochemistry (IHC) and immunoﬂuorescence
Parafﬁn-embedded human prostate cancer TMAs were purchased from
US Biomax (Rockville, MD, USA). The sections were treated and stained
as previously reported.30 For IHC, 3 3' diaminobenzidine staining was
performed using Dako Real Detection Systems LSAB+ (K5001, Agilent
Technologies, Santa Clara, CA, USA).
IHC for PML and CRM1 expression in patient’s prostate cancer
samples
Patient selection and TMA construction. A TMA was constructed from
formalin-ﬁxed wax-embedded tumour and benign tissue samples col-
lected from 192 patients diagnosed between 1999 and 2001 at the
Nottingham City Hospital, UK. Two 0.6 mm tissue cores (per patient) of
trans-urethral resection of prostate or radical prostatectomy specimens
with a histological diagnosis of cancer were assembled using a Grand
Master arrayer (3DHistech Ltd, Budapest, Konkoly-Thege Miklós út,
Hungary). Multiple clinicopathological variables were recorded for each
patient and the patient characteristics are shown in Supplementary Table 1.
Use of the tissue samples for this study was approved by the North
West 7 Research Ethics Committee–Greater Manchester Central REC
number 10/H1008/72.
IHC and analysis. Sections (4 μm) were subjected to microwave antigen
retrieval in 10mM sodium citrate, pH 6 and immunostained using the PML
(1:300) and CRM1 (1:100) antibodies. Antibody localization and detection
were achieved using Novolink reagents (Leica, Milton Keynes, UK), a
diaminibenzidine chromogen and haematoxylin counterstain.
Stained TMA sections were microscopically assessed (DGP, GVS)
to semi-quantify the level of protein expression in the nuclei and
cytoplasm of malignant prostate tissue using a Histochemical scoring
(H-score) technique resulting in a score between 0 and 300.31
Patients were dichotomously categorized for biomarker expression
using the software programme X-tile to determine the optimal cutoff.32
The cutoff values used were PML: nuclear (230), cytoplasm (80);
CRM: cytoplasm (110). Patients were classiﬁed according to PML and
CRM1 expression patterns (Supplementary Table 2) and a Kaplan–Meier
survival plot performed to compare the different classes according
to disease-speciﬁc survival. Subsequently, a group of patients
exhibiting a poor prognosis was deﬁned on the basis of an absence of
PML and CRM1 expression, or simultaneous cytoplasmic expression of
PML and CRM1.
REMARK guidelines for reporting on prognostic biomarkers were
followed and a ﬂow diagram showing the ﬁnal number of cases that
were analysed as a proportion of the whole cohort is shown in
Supplementary Figure 1.33 Following immunostaining, the number of
samples available for analysis was reduced for several reasons: the amount
of available malignant tissue was considered too small to be representative
of the tumour, tissue cores were detached during processing, cases had
data for only one biomarker/case or clinical data (survival or metastasis)
were not available for follow-up.
Liquid chromatography-matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry identiﬁcation of
PML-interacting partners
Following IP, identiﬁcation of the potential interacting partner proteins was
carried out by LC-MALDI mass spectrometry. Samples were tryptically
digested and fractionated by nano-LC (C18 PepMap100, 150mm×75 μm;
5 μm particle size) before spotting in 10 s fractions over a 384-spot target
plate. Analysis was carried out on a Bruker UltraﬂeXtreme MALDI-TOFTOF
mass spectrometer (Bruker Daltonics, Banner La, Coventry, UK) in
reﬂectron-positive mode over a m/z range of 650–3500. Tandem mass
spectrometry fragmentation of the top 10 precursors per spot was carried
out and results exported using Biotools 3.1 software (Bruker Daltonics) for
searching via Mascot 2.1 against the human Swissprot database.
Cell migration and invasion assays
For wound healing assay (Scratch assay), DU145 and PC3 cells expressing
the empty vector, PMLI WT-HA, PMLI ΔNLS-HA and PMLI ΔNES-HA were
cultured to 80% conﬂuence and serum starved for 24 h, after which a
scratch was made in the middle of each well using a 10-μl pipette tip.
Images from triplicate experiments at 0 and 24 h were taken and the
distances between the edges of the scratch were measured at three
different points using Carl Zeiss AxioVision software (Carl Zeiss,
Oberkochen, Germany). The measurements were expressed as percen-
tages of gap closure. For the well cell migration and invasion assay, we
used Cultrex 96-Well Cell Migration Assay (3465-96-K, Cultrex) and Cultrex
96-Well BME Cell Invasion Assay following the manufacturer’s recom-
mendations (Trevigen, Gaithersburg, MD, USA). The cells in the bottom
chamber were labelled by Calcein AM (Trevigen) and the quantiﬁcation
of the number of cells was performed using the plate reader Inﬁnite
M200 Pro TECAN (Tecan Group Ltd, Männedorf, Switzerland) at 585 nm
excitation and 520 nm emission.
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